What is the appropriate evaluation and management for urticarial vasculitis?

Urticarial Vasculitis: Evaluation and Management

Diagnostic Approach

Urticarial vasculitis requires skin biopsy for definitive diagnosis, showing leukocytoclastic vasculitis with fibrinoid necrosis, endothelial damage, perivascular fibrin deposition, and red cell extravasation. 1

Key Clinical Features Distinguishing UV from Ordinary Urticaria

• Lesion duration >24 hours (versus 2-24 hours in ordinary urticaria) 1, 2
• Post-inflammatory hyperpigmentation or ecchymotic residua after lesions resolve 2, 3
• Pain or burning sensation rather than pure pruritus 2
• Individual wheals persist for days rather than hours 1

Essential Laboratory Workup

Once histologic diagnosis is confirmed, perform a complete vasculitis screen 1:

• Complement levels (C3, C4) to distinguish normocomplementemic from hypocomplementemic disease 1
• C1q levels (reduced in hypocomplementemic UV with worse prognosis) 1
• Complete blood count, ESR, CRP 4
• Antinuclear antibodies 4
• Screen for underlying systemic disease including joint and renal involvement 1

Hypocomplementemic UV carries a significantly worse prognosis and requires more aggressive management. 1

Treatment Algorithm

Mild Cutaneous Disease (UVAS7 ≤7 of 70)

Start with second-generation H1-antihistamines at standard doses as first-line therapy 1, 5, 6:

• Cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, or mizolastine once daily 1
• If inadequate response, increase antihistamine dose up to 4-fold above standard dosing 1, 6
• Add NSAIDs for symptomatic relief 5

Important caveat: Unlike ordinary urticaria, antihistamines are often ineffective in UV, with most patients requiring additional therapy 7.

Intermittent Cutaneous Disease

Short courses of systemic corticosteroids (typically 0.5-1 mg/kg prednisone equivalent) 5, 7:

• Effective in >80% of patients for skin symptoms 7
• Limit duration to avoid long-term adverse effects 1

Refractory or Hypocomplementemic Disease (UVAS7 >7)

Initiate corticosteroid-sparing immunomodulatory agents with comparable efficacy 5, 6:

First-line steroid-sparing options (choose based on patient factors and drug availability):

• Hydroxychloroquine 200-400 mg daily 5, 7
• Dapsone 50-150 mg daily (check G6PD before initiating) 5, 7
• Colchicine 0.6-1.2 mg daily 5, 7

These three agents show comparable efficacy and are preferred for chronic management 5.

Persistent Symptoms Despite Above Measures

Add conventional immunosuppressants 5, 6, 7:

• Azathioprine 1-2 mg/kg/day
• Mycophenolate mofetil 1-3 g/day
• Methotrexate 7.5-25 mg weekly
• Cyclosporine A 3-5 mg/kg/day
• Cyclophosphamide (reserved for severe systemic disease)

Refractory Disease with Systemic Involvement

Consider biologic therapies 5, 6, 7:

• Omalizumab 300 mg subcutaneously every 4 weeks (can follow chronic urticaria algorithm) 6, 7
• Anti-IL-1 agents (canakinumab, anakinra) for severe cases 5, 6
• Rituximab for severe refractory disease 5, 7
• Plasmapheresis for acute severe exacerbations 5, 7

Multidisciplinary Management Required

Hypocomplementemic UV and systemic involvement necessitate collaboration with rheumatology 6:

• Screen for systemic lupus erythematosus, malignancy, and infections 4, 7
• Monitor for renal disease, arthritis, and other organ involvement 1
• Consider underlying causes: drugs, autoimmune disease, malignancy, infections 7

Critical Management Pitfalls

Do not rely on antihistamines alone - they are ineffective as monotherapy in most UV patients, unlike ordinary urticaria 7. H2-antihistamines, montelukast, and doxepin show poor efficacy 7.

Do not delay skin biopsy - clinical diagnosis alone is insufficient, as UV can mimic chronic spontaneous urticaria but requires fundamentally different management 1, 4, 8.

Always check complement levels - distinguishing normocomplementemic from hypocomplementemic disease is essential for prognosis and treatment intensity 1.

Avoid prolonged corticosteroid monotherapy - while effective acutely, long-term use causes significant adverse effects; transition to steroid-sparing agents early 1, 5.

Prognosis

The prognosis for eventual recovery from urticarial vasculitis is excellent, though some cases may be persistent 1. Hypocomplementemic disease has worse outcomes and requires more aggressive management 1.